New Blood-Filtering strategy aims to save lives from weed killer poisoning
NCT ID NCT07234383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether starting a specific type of blood filtering (hemodiafiltration) immediately after a standard blood-cleaning treatment (hemoperfusion) can improve survival in people with severe diquat poisoning. Diquat is a herbicide that can cause rapid kidney failure and death. The study will enroll 24 adults with high levels of diquat in their blood. Researchers will track how many survive and how long they live, aiming to see if this faster approach is safe and promising enough for larger studies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Continuous veno-venous hemodiafiltration (a type of blood filtering procedure)
- What this could lead to
- If successful, this could establish a faster, more effective way to filter the blood after diquat poisoning, potentially reducing deaths.
- What could go wrong
- This is a very early, small (24 people) single-arm trial with no comparison group. The approach may not improve outcomes and carries risks from the procedure itself, like bleeding or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2027
An estimate. Start dates often move.
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: 1. Age ≥ 18 years; and 2. A history of oral exposure to diquat solution, reported by patient(s) or their legal proxies; and 3. An exposure time (time form exposure to presentation at ED) ≤ 48 hours, reported by patient(s) or their legal proxies; and 4. Plasma diquat concentration measured upon ED presentation ≥ 1,000 ng/mL. Exclusion criteria: 1. Evidence of co-ingestion of other toxic substances alongside diquat; and/or 2. Withholding of CVVHDF due to limitations on the escalation of life-sustaining therapies; and/or 3. Any CKRT within the previous 2 months; and/or 4. Kidney transplant within the past 365 days; and/or 5. Known pre-hospitalization advanced chronic kidney disease, defined by an estimated glomerular filtration rate calculated using serum creatine (eGFRer) of less than 30 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, if pre-hospitalization serum creatine is available; and/or (6) Treating clinician(s) believe(s) that either immediate or deferral of CVVHDF initiation is mandated; and/or (7) Pregnant or breast feeding.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diquat poisoning are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.